.png){kind=icon}
.png){kind=icon}
Return
Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer
.png){kind=icon}
OA
AI
Y
H
X
L
DOI：10.1016/j.cllc.2026.06.002.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To investigate the prognostic value of pretreatment SUVmax in early-stage NSCLC treated with stereotactic body radiotherapy (SBRT) and evaluate whether metabolic activity modulates the impact of overall treatment time (OTT) on outcomes.
Keywords:
Non-small cell lung cancer
Stereotactic body radiotherapy
SUVmax
Overall treatment time
Local control
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.3
Papers:
2.4K
Citations:
4.5K
Organization
Cited Papers